NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
(WorldNews Switzerland)

Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved event-free survival in FLT3-mutated AML versus chemotherapy alone First publication of RATIFY data following ASH 2015 presentation; result of over a decade`s collaboration with Alliance for Clinical Trials inOncology/CALGB Basel, June 23, 2017- Novartis today announced that full results from the Rydapt [®] (midostaurin) Phase III RATIFY (CALGB 10603 [Alliance]) clinical trial were published in The New England Journal of Medicine (NEJM) [1]. Top-line data from this study were previously presented...